Richard I. Steinhart, Chief Financial Officer at BioXcel Therapeutics, Inc. (BTAI), sold 577 shares at $0.36 ($208) on 2024-12-16, disclosed to the SEC on 2024-12-17.
Scheduled sale ($208) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.36 | 205 | $74 | 35.5% |
| 2 | $0.36 | 372 | $134 | 64.5% |
| Total | $0.36 avg | 577 | $208 | 100% |
| Filing → |
| BTAI | SELL | 2024-09-17 | $246 | — | Filing → |
| BTAI | SELL | 2024-06-18 | $469 | — | Filing → |
| BTAI | SELL | 2024-04-08 | $3K | — | Filing → |